LEO Pharma Enters Supply and Distribution Agreement with NeoPharm on Non-Prescription Skin Care Solutions
LEO Pharma A/S a global healthcare company dedicated to helping people achieve healthy skin, and NeoPharm Co., Ltd., (KOSDAQ: A092730) a specialist in sensitive skin care, today announced that the companies have entered into a 10 year’s agreement of supply and distribution of a selection of skin care products within NeoPharm’s range of products.
Ballerup, Denmark and Daejeon, Korea, 2 June 2015 – Under the terms of the agreement, products will be manufactured and supplied by NeoPharm and marketed and distributed by LEO Pharma as non-prescription skin care under a LEO Pharma trademark. NeoPharm has developed the products using their proprietary technology MLE® (Multi-Lamellar Emulsion), Defensamide™ and ADfence-P™. LEO Pharma will have the rights to market the products globally – except for Korea, Thailand, Indonesia, Pakistan, Singapore, Malaysia, UAE and the Philippines.
“We are very pleased to enter into this collaboration with NeoPharm. This deal reflects LEO Pharma’s increased commitment to a more holistic approach to care,” said Lars Olsen, Executive Vice President for Global Sales & Marketing at LEO Pharma. “By offering a portfolio of emollients we can provide help to patients not only during treatment periods but also during their daily care routines for their skin”.
“We are very excited about this opportunity to make a selected part of our innovative skin-barrier restoring products broadly available through LEO Pharma’s large sales network,“ said Dr Park, CEO of NeoPharm Co., Ltd.
LEO Pharma is increasing its focus on meeting the unmet needs of people living with skin diseases. By entering partnerships with innovative companies, like NeoPharm, LEO Pharma wants to bring new dermatology solutions to patients – faster.
Spain will be the first of several markets to gain access to the new LEO Pharma emollients portfolio. This is expected to happen during 2015.
About LEO Pharma A/S
LEO Pharma helps people achieve healthy skin. By offering care solutions to patients in more than 100 countries globally, the company supports people in managing their skin conditions. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to delivering products and solutions to people suffering from skin diseases. LEO Pharma is headquartered in Denmark and employs around 4,800 people worldwide. For more information, visit www.leo-pharma.com
About NeoPharm Co., Ltd
NeoPharm provides trustworthy quality cosmetics and drugs through innovative R&D to those who pursuits the beautiful and healthy life lifestyle. NeoPharm is one of the market-leading companies in the emollients market in Korea. NeoPharm is listed on the KOSDAQ exchange in Korea. NeoPharm is the inventor of Multi-Lamellar Emulsion (MLE®
), Defensamide™ and ADfence-P™ technology. For more information, visit www.neopharm.co.kr/en/
About Multi-Lamellar Emulsion (MLE®) technology
MLE® is original technology from NeoPharm that mimics the lamellar structure of the natural skin lipids and provides the ultimate in revitalizing the skin's moisture through the restoration of the protective barrier system. The special cross pattern of the MLE® shows that it is identical to the lipid lamellar structure of the skin. MLE® is mild and skin friendly because the structure of plant derived ceramides, fatty acids and cholesterol is identical to that of the lipid lamellar structure of the skin. The restoration of the skin barrier system enables it to successfully lock in moisture and help protect the skin from environmental stresses.